Blood-Tumor Barrier’s Role in Brain Mets

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.

In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.

Recent Videos
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
Related Content
The investigators noted no new safety signals were reported in this trial.

Isa-VRd Meets Primary End Point in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Ariana Pelosci
September 20th 2025
Article

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

MRD Negativity Improves With Daratumumab Maintenance Combo in NDMM

Ashling Wahner
September 20th 2025
Article

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Belantamab Mafodotin Triplet Highlights Low Ocular Toxicity in Intermediate-Fit, Frail Newly Diagnosed Myeloma

Belantamab Mafodotin Triplet Highlights Low Ocular Toxicity in Intermediate-Fit, Frail Newly Diagnosed Myeloma

Ashling Wahner
September 20th 2025
Article

Belantamab mafodotin plus lenalidomide and dexamethasone yielded a stringent CR of 42.9% in patients with newly diagnosed multiple myeloma.

Daratumumab Quadruplet Improves Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma

Daratumumab Quadruplet Improves Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma

Caroline Seymour
September 20th 2025
Article

Daratumumab, lenalidomide, ixazomib, and dexamethasone yielded PFS/OS outcomes in transplant-ineligible, newly diagnosed myeloma.